Neoadjuvant Darovasertib in Primary Uveal Melanoma
Status:
RECRUITING
Trial end date:
2031-03-01
Target enrollment:
Participant gender:
Summary
This is a Phase 3, randomized, multi-center, open-label study of neoadjuvant darovasertib in subjects with primary non-metastatic uveal melanoma (OptimUM-10)